Evidence map›Paper›PMID 28405526›Full record

ArticleOncoimmunology

Anti-VEGFR2-interferon-α2 regulates the tumor microenvironment and exhibits potent antitumor efficacy against colorectal cancer.

Zhaoting Li, Yijia Zhu, Chenchen Li, Ryan Trinh, Xueyan Ren, Fumou Sun, Youfu Wang, Pengzhao Shang, Tong Wang, Min Wang and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 22 citations in OpenAlex.

  1. Review
  2. Targeting inflammation as cancer therapy.Journal of hematology & oncology · 2024
    Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. VEGFR2-targeted antibody fused with IFNActa pharmaceutica Sinica. B · 2021
    Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 2 institutions in 2 countries.

Zhaoting LiAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Yijia ZhuAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Chenchen LiAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Ryan TrinhDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles , Los Angeles, CA, USA.
Xueyan RenAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Fumou SunAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Youfu WangAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Pengzhao ShangAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Tong WangAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Min WangAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
Sherie L MorrisonDepartment of Microbiology, Immunology and Molecular Genetics, University of California Los Angeles , Los Angeles, CA, USA.
Juan ZhangAntibody Engineering Laboratory, School of Life Science and Technology, State Key Laboratory of Natural Medicines, China Pharmaceutical University , Nanjing, China.
China Pharmaceutical University · CNUniversity of California, Los Angeles · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Interferon-α (IFNα) has multiple antitumor effects including direct antitumor toxicity and the ability to potently stimulate both innate and adaptive immunity. However, its clinical applications in the treatment of malignancies have been limited because of short half-life and serious adverse reactions when attempting to deliver therapeutically effective doses. To address these issues, we fused IFNα2a to the anti-vascular endothelial growth factor and receptor 2 (VEGFR2) antibody JZA00 with the goal of targeting it to the tumor microenvironment where it can stimulate the antitumor immune response. The fusion protein, JZA01, is effective against colorectal cancer by inhibiting angiogenesis, exhibiting direct cytotoxicity, and activating the antitumor immune response. Although JZA01 exhibited reduced IFNα2 activity

Indexed as

CD8+ T cellscolorectal cancerDCsIFNα2tumor microenvironmentVEGFR2

Identifiers

PMID28405526
PMCPMC5384376
OpenAlexW2588029744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.